NCT03871257 2026-04-13
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
25 trialsNCT04724369 2026-04-03
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 3 Active not recruiting
NCT05095376 2026-04-03
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology
Phase 3 Active not recruiting
NCT05438212 2026-04-03
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NRG Oncology
Phase 3 Active not recruiting
NCT03663725 2026-03-30
StrateGlio
Centre Oscar Lambret
Phase 3 Active not recruiting
NCT04924608 2026-03-23
KOMET
AstraZeneca
Phase 3 Active not recruiting
NCT01592968 2026-03-09
Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT00950001 2026-02-20
Stereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT04739761 2026-02-11
DESTINY-B12
AstraZeneca
Phase 3 Active not recruiting
NCT04114981 2026-01-26
Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT00887146 2026-01-22
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT02176967 2025-12-22
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Children's Oncology Group
Phase 3 Active not recruiting
NCT04939597 2025-12-22
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
Children's Oncology Group
Phase 3 Active not recruiting
NCT05326464 2025-12-15
Tofacitinib in Recurrent GBM Patients
University of Texas Southwestern Medical Center
Phase 3 Active not recruiting
NCT05902169 2025-11-10
SONOBIRD
CarThera
Phase 3 Active not recruiting
NCT02685605 2025-10-14
INTRAGO-II
Universitätsmedizin Mannheim
Phase 3 Active not recruiting
NCT04365374 2025-10-07
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
GT Medical Technologies, Inc.
Phase 3 Active not recruiting
NCT04674683 2025-09-24
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
HUYABIO International, LLC.
Phase 3 Active not recruiting
NCT07165262 2025-09-10
ECOG-Anaes
Children's Cancer Hospital Egypt 57357
Phase 3 Active not recruiting
NCT00978458 2025-09-08
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT00392327 2025-06-13
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
Children's Oncology Group
Phase 3 Active not recruiting
NCT04164901 2025-04-03
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Servier
Phase 3 Active not recruiting
NCT05913037 2025-03-06
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3 Active not recruiting
NCT05118776 2024-10-31
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
Ascletis Pharma Inc
Phase 3 Active not recruiting
NCT00626990 2023-09-11
CATNON
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting